Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
Most conversations about regenerative medicine focus on the procedure itself: the fat collection, the cell culture and the infusion. For international patients, an equally important question is what happens afterward. Once you return to your home country, who will monitor how you feel, and how will you reach the clinic if something changes? This article outlines practical points to think about before you travel to Osaka for adipose-derived stem cell therapy. It is general information, not medical advice, and it cannot replace a consultation with a physician.
Why follow-up planning matters for medical travelers
Adipose-derived stem cell therapy involves collecting a very small amount of your own fat tissue, culturing the mesenchymal stem cells it contains at a specialized facility, and returning the cells to your body by intravenous infusion. Because the culture period sits between the two visits, the treatment is rarely a single-day event. Patients who live abroad therefore need to think about the whole timeline, including the days after each visit.
Published research on mesenchymal stem cells is still developing, and reported outcomes vary between studies, conditions and individuals. For that reason, responsible follow-up is not about proving that a treatment worked. It is about noticing any unexpected changes early, recording your own observations in a consistent way, and making sure a qualified physician can interpret them.
Questions to ask your doctor before you leave Japan
A consultation at Grand Green Osaka Umekita Clinic is the right place to ask how follow-up is handled in your specific situation. Because every patient has a different medical history, the doctor is the person who can explain what applies to you. It can help to bring a written list of questions, such as the following.
- Which symptoms after fat collection or infusion are considered expected, and which should prompt contact with the clinic?
- How long should I stay in the Osaka area after the infusion before traveling by air?
- Is there a recommended schedule for check-ins, and can these be done remotely or only in person?
- Should I tell my regular physician at home about the treatment, and what information should I give them?
- Are there medications or supplements I should discuss with the doctor before or after treatment?
Asking these questions in advance avoids the uncertainty of trying to reach a clinic across time zones when something feels unfamiliar.
Keeping clear records you can share with your home physician
Many patients return home with only a verbal memory of what was done. A better approach is to request and organize documents that describe the treatment you actually received. Ask the clinic what written information can be provided, for example the dates of fat collection and infusion, the general nature of the procedure, and any instructions given to you at discharge. If a translated summary is available, that can make a conversation with a local doctor easier, although you should confirm with the clinic what documents it is able to supply.
It is also useful to keep a simple personal log. Note the date, any symptoms, any medication you take, and how you feel in everyday activities. A log is not a diagnostic tool, but it gives both you and your physicians a more reliable picture than memory alone. Avoid drawing conclusions from small day-to-day changes, since many factors, including sleep, stress and weather, can influence how you feel.
Understanding the regulatory framework and what it means for aftercare
In Japan, regenerative medicine of this kind is provided under the Act on the Safety of Regenerative Medicine, which requires institutions to submit a treatment plan and to follow defined procedures for cell processing and safety management. This is a self-pay (non-insured) treatment, which means it is not covered by national health insurance. Costs, risks, possible side effects and suitability must be confirmed directly with a doctor during a consultation.
The legal framework is designed to support safety management, but it does not guarantee any particular result for an individual patient. It is therefore reasonable to ask the clinic how it records and responds to reported health concerns after treatment, and what the process is if you need to report a problem once you are abroad.
Staying connected after you return home
Practical communication is easy to overlook. Before you leave, confirm which contact methods the clinic uses for international patients, what languages are supported, and what response times to expect given the time difference between Osaka and your home country. Grand Green Osaka Umekita Clinic is located in the Umeda area, and it provides an information page for foreign patients, which is a helpful starting point for understanding how inquiries are handled.
Also decide in advance how you will handle urgent situations. If you develop symptoms that worry you, seek care from a local physician or emergency service right away rather than waiting for a reply from overseas, and then let the clinic know afterward. Having the name and contact details of a regular doctor at home, and telling them about your treatment, can make that situation much simpler.
Keeping expectations realistic and continuing standard care
Stem cell therapy is not a substitute for the standard medical care recommended for your condition. Continue to follow the advice of your usual physicians, attend scheduled check-ups, and do not stop or change prescribed medications without medical guidance. If you have a chronic condition such as osteoarthritis, your regular doctor remains an important partner in managing it.
Because individual responses differ and evidence continues to evolve, it is wise to avoid fixed expectations about timing or degree of change. Discuss with your doctor how progress might be reviewed over time and what would be a sensible way to decide whether any further steps are appropriate.
Summary
For international patients, good aftercare planning begins before the first visit. Prepare your questions, request clear records of what was done, keep a simple personal log, understand that this is a self-pay treatment provided under Japan’s regenerative medicine law, and agree on how you will stay in touch once you are home. If you are considering adipose-derived stem cell therapy in Osaka, the next step is a consultation with a doctor, who can explain the risks, side effects, costs and suitability for your circumstances.
- 1Prepare questions
- 2Request records
- 3Keep a simple log
- 4Agree how to stay in touch
- 5Consult a doctor
This diagram is a conceptual summary of the article content
References
- PubMed: Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial. (2025)
- PubMed: Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). (2017)
- PubMed: Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study. (2024)
- PubMed: Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). (2023)
- PubMed: Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. (2018)
- PMC: A prospective single-arm study on the effects of repeated intravenous infusions of canine adipose-derived mesenchymal stromal cells in dogs with chronic inflammatory enteropathy. (2025)
- PMC: Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial. (2026)
- PMC: Functional recovery of a 41-year-old quadriplegic spinal cord injury patient following multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells: a case report. (2023)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.